biostudies-literatureUnknown9(2)Garnier MFrench Ministry of Health &quot;Programme Hospitalier de Recherche Clinique&quot;Biorad Laboratory<h4>Introduction</h4>The dramatic increase of the incidence of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) has led to an increase of 50% of carbapenem consumption all around Europe in only 5 years. This favours the spread of carbapenem-resistant Gram-negative bacilli (GNB), causing life-threatening infections. In order to limit use of carbapenems for infections actually due to ESBL-PE, health authorities promote the use of rapid diagnostic tests of bacterial resistance. The objective of this work conducted in the intensive care unit (ICU) is to determine whether an early de-escalation of empirical carbapenems guided by the result of the βLACTA test is not inferior to the reference strategy of de-escalating carbapenems after the antibiogram rBMJ opene024561https://www.ebi.ac.uk/biostudies/studies/S-EPMC6367973biostudies-literatureMulticentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.PMC6367973Maury EGuerot ECardot-Martin EBercot BAissa NBruel CGallah SDjhouri SLescot TMegarbane BRiegel PJacquier HFaibis FBosi CBlondel EDesebbe OHerault MCFoufa MHBreuil JPoupet HCompain FSiami SQuesnel CTchir MGuerci PDecousser JWBert FGalliot RTamion FFarrugia CGrossmith GBenzerara YBurucoa CThierry JCaspar YVeber BPestel MVimont SMontil MLorme FJoubrel-Guyot CLabbe VMainardi JLWeiss EKempf MMongardon NRouard CConstant ALLegrand MMertes PMLemonnier ADeclercq PLTrouiller PFave GGarnier MBLUE-CarbA study group.Roche ACPommier JDLasocki SDahyot-Fizelier CHuan Ha VHfalseMulticentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.<h4>Introduction</h4>The dramatic increase of the incidence of infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) has led to an increase of 50% of carbapenem consumption all around Europe in only 5 years. This favours the spread of carbapenem-resistant Gram-negative bacilli (GNB), causing life-threatening infections. In order to limit use of carbapenems for infections actually due to ESBL-PE, health authorities promote the use of rapid diagnostic tests of bacterial resistance. The objective of this work conducted in the intensive care unit (ICU) is to determine whether an early de-escalation of empirical carbapenems guided by the result of the βLACTA test is not inferior to the reference strategy of de-escalating carbapenems after the antibiogram r2019-01-01T00:00:00Z2019 Feb2026-05-03T17:09:34.061Z2019-06-06T20:50:43ZS-EPMC63679733078290910.1136/bmjopen-2018-024561